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1. Introduction
Even with the progress that has been made in the past years on our understanding of Alz‐
heimer’s disease (AD) we don’t seem to be closer to finding a cure than we were before. AD
is a complex disorder wherein the pathophysiology is influenced by a great number of
environmental and genetic factors, thus making it difficult to uncover the triggering events
underlying disease’s onset. In this chapter, we will first discuss some common conditions
within the general population that have been associated with an increased risk to develop late-
onset Alzheimer’s disease (LOAD), such as hypertension, type 2 diabetes mellitus and high
serum cholesterol and triglycerides levels, and the way they might be contributing to cognitive
decline; depression and traumatic brain injuries, amongst others, will also be boarded.
Misdiagnosis is a frequent issue with important repercussions not only for the patient’s
condition but also for family members. For this reason, in the second part we will review the
main basic aspects that should be involved in AD diagnosis, from laboratory tests to neuroi‐
maging technologies, highlighting the importance of seeking a differential diagnosis of
dementias in the elderly and the crucial role an accurate diagnosis may play in therapeutic
outcomes as well as the implications for quality of life.
Early diagnosis of Alzheimer’s may be the best tool we could find, as for now, to improve
treatment outcomes by slowing the disease progression rate. This idea has led an important
number of scientists around the globe to the search for biomarkers using a wide variety of
approaches in the brain, cerebrospinal fluid (CSF) and blood. On this matter, we will briefly
comment on our preliminary study using lymphocytes from cognitively healthy people and
neuropsychological patients affected not only with LOAD but other types of neuropathologies
as well to analyse in blood cells the expression of the main genes directly related to AD in brain
cells. This study included 72 subjects in whom the expression of the microtubule-associated
© 2013 Herrera-Rivero; licensee InTech. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
protein tau (MAPT), the amyloid precursor protein (APP), nicastrin (NCSTN), a component
of the γ-secretase, and β-secretase (beta-site APP cleaving enzyme 1, BACE1) were analysed
through 4 groups of cognitively healthy individuals ranging from 25 to 92 years of age and in
conditions such as LOAD, vascular dementia (VaD) and Parkinson’s disease (PD) in elderly
individuals. We also aimed to discover the manner in which the expression of these genes
might be affected by conditions associated with increased risk for LOAD such as hypertension
and glucose, cholesterol and triglycerides serum levels.
2. Risk factors for AD
A wide variety of factors have been associated with an increased risk to develop LOAD;
nevertheless, a number of these associations remain controversial. Age is the main risk factor
to develop AD of the sporadic type and is only followed by apolipoprotein E (ApoE) genotype.
However, other genetic and environmental conditions have also been proven to influence the
risk of developing the disease and the rate of cognitive decline which affects disease progres‐
sion. Amongst these are found cardiovascular risk factors, type 2 diabetes mellitus, sleep
disorders, depression, education, smoking, alcohol, traumatic brain injury (TBI) and several
single nucleotide polymorphisms (SNPs) in a growing list of candidate genes.
2.1. Environmental
a. Cardiovascular risk factors.
Within the risk factors for vascular disease hypertension and high cholesterol levels are most
importantly associated with LOAD. Various longitudinal studies have shown an association
between a diagnosis of hypertension in midlife and the development of AD in late life [1,2].
On this regard, hypertension may cause cerebrovascular disease which would contribute to
accelerate AD processes, even when there are reports on a decrease in blood pressure during
the disease course probably due to affection of the brain regions implicated in its regulation
[3]. Cholesterol and its metabolism is associated with AD by several proposed mechanisms
including regulation of beta-amyloid (Aβ) generation by an increase in β-secretase activity,
APP membrane localization and cleavage variations by changes in cholesterol rich lipid rafts
and ApoE-regulated interactions between cholesterol and Aβ.
b. Type 2 diabetes mellitus.
Diabetes and even high glucose levels in the absence of a diabetes diagnosis are associated
with an increased risk to develop AD involving various mechanisms, primarily being changes
in the blood brain barrier (BBB) and the transport within cerebral small vessels [4].
c. Traumatic brain injury.
TBI has been associated with an increased risk to develop AD by longitudinal and retrospective
studies, suggesting an effect between severity and repetitive episodes of TBI particularly by
an increase in amyloid deposition [5, 6].
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d. Depression.
It has been subject for debate whether depression might be an early manifestation of AD or a
contributing factor for development of the disease. If one thing is sure is that depression
contributes to cognitive decline and may by itself cause a condition known as “depressive
pseudo-dementia” which can frequently evolve to a true dementia (mainly AD) when not
treated, particularly in the elderly [7]. A history of major depressive disorder or susceptibility
to depression during an individual’s lifetime has therefore been associated with an increased
risk to develop LOAD [8].
e. Sleep.
Chronic sleep deprivation and other sleep disorders have a negative effect on cognitive
function primarily due to the role sleep plays in memory and learning processes and possibly
in synaptic plasticity, although it is also believed there is an increase in Aβ during the waking
hours [9]. History of sleep disorders has thus been linked to an increase in the risk to develop
LOAD; furthermore, sleep disorders occurring as part of the aging process and those related
to coexisting medical conditions contribute to cognitive decline and behavioural problems in
AD patients.
f. Education.
People with a lower level of education show an increased risk to develop LOAD. This might
be due to the relative lack of constant stimulation of cognitive processes (such as learning and
memory) compared to individuals with a higher education degree. In fact, cognitive stimula‐
tion therapies are widely used for helping the treatment of people with dementia [10].
g. Diet.
It is well known that diet affects every aspect of an individual’s health. A number of medical
conditions associated with an increased risk for developing AD have a strong nutritional
background as cholesterol, glucose and vitamin B12 levels, just to mention a few, importantly
influence the risk for dementia [11], particularly in old age.
h. Alcohol and smoking.
It remains unclear whether alcohol and smoking increase the risk for AD as their association
has been inconsistent. Although smoking is a strong risk factor for vascular disease, and the
association of the latter with AD has been established, the possibility of a neuroprotective effect
of nicotine by a smoking-induced increase in nicotinic receptors exists [3]. Similar is the case
of alcohol where wine presents protective effects because of its antioxidant contents while
associations between other types of alcohol and risk of AD remain controversial.
2.2. Genetic
Medical conditions and lifestyle in midlife, especially when a group of these factors coexist in
an individual creating a synergistic effect, can contribute to cellular and molecular alterations
ultimately leading to the hallmark pathological processes of AD later in life. Although
Late–Onset Alzheimer’s Disease: Risk Factors, Clinical Diagnosis and the Search for Biomarkers
http://dx.doi.org/10.5772/53775
37
environmental factors appear to play an important role in the development of LOAD, a number
of them may depend on a genetic-influenced predisposition. Genetic variations in candidate
genes have been widely investigated for associations with an increased risk of development,
age of onset and progression of AD and, while results on several studies are controversial or
inconclusive, it remains clear that common genetic variations do associate with LOAD whether
in a general or population-specific manner. The AlzGene database holds information on 2973
polymorphisms in 695 genes reported in 1395 studies. We summarize in Table 1 some of the
main findings on this field.
Gene Chromosome SNP Odds ratio Studies
APOE 19 e2/3/4 3.68 (4 vs. 3) 37
BIN1 2 rs744373 1.17 21
CLU 8 rs11136000 0.89 33
ABCA7 19 rs3764650 1.23 10
CR1 1 rs3818361 1.15 27
PICALM 11 rs3851179 0.88 27
MS4A6A 11 rs610932 0.90 11
CD33 19 rs3865444 0.89 5
MS4A4E 11 rs670139 1.08 11
CD2AP 6 rs9349407 1.12 5
EPHA1 7 rs11767557 0.89 5
GSTO1 10 rs4925 0.97 7
TOMM40 19 rs8106922 0.66 7
SORL1 11 rs2282649 1.10 23
PVRL2 19 rs6859 1.50 8
NCSTN 1 rs2274185 0.90 5
BDNF 11 270C/T 1.09 20
GAB2 11 rs2373115 0.85 13
Source: Meta-analysis for all studies from AlzGene-field synopsis of genetic association studies in AD (www.alzgene.org)
Table 1. Some widely studied genetic variations associated with an increased risk of AD.
At this point there is a need to highlight that prevention of LOAD may only be achieved by a
healthy lifestyle implemented early in life, most importantly by those individuals with a
genetic susceptibility.
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3. Clinical diagnosis of LOAD
To perform a clinical diagnosis of AD or other dementias may not be challenging when
symptoms are from moderate to severe and well differentiated; however, it might be more
difficult to achieve an accurate diagnosis in the early stages of the disease,  especially in
elderly individuals where initial manifestations of AD can be taken as an effect of aging.
Early detection of cognitive decline in primary care thus becomes crucial for canalization
of the patient to an adequate specialist and a subsequent early accurate diagnosis which
allows  a  better  management  of  disease  progression.  In  the  first  stages  of  AD,  memory
processes are the most affected but since a number of other treatable medical conditions
also present with deficiencies in memory performance, a differential diagnosis based on all
available  tools  must  always  be  pursued.  Clinical  diagnosis  of  LOAD  should  include
laboratory and neuropsychological tests as well as structural and functional imaging of the
brain which, together with the clinical history and interviews with those living closest to
the patient, would provide a better idea of the patient’s overall condition.
3.1. Initial evaluation
Clinical history and, importantly, interviews with close family members and friends provide
valuable information on patient’s medical history, lifestyle and disease onset and progression.
Several issues may be considered though when evaluating an aged individual: clinical
manifestations of psychiatric disorders differ from younger patients; life events, social and
financial situations as well as physical status are also relevant aspects to be taken into account.
3.2. Laboratory tests
Running laboratory tests is important to identify secondary causes of dementia and medical
conditions common in the aged population. It  is  advisable to perform a complete blood
count,  serum  electrolytes,  glucose,  vitamin  B12,  BUN/creatinine  ratio  and  thyroid  and
hepatic  function  panels.  Electrocardiography  (ECG),  electroencephalography  (EEG)  and
thorax x-rays can also be included. Increase in total tau protein (t-tau) and decrease in Aβ42
in CSF are found in AD.
3.3. Neuropsychological evaluation
Neuropsychological evaluation is fundamental for dementia diagnosis providing evidence
of cognitive dysfunction and specific patterns helping to uncover the cause. AD diagnosis
is  based  on  NINCDS-ADRDA  (National  Institute  of  Neurological  and  Communicative
Disorders and the Alzheimer’s Disease and Related Disorders Association) criteria and is
classified as definitive (clinical diagnosis with histological confirmation), probable (typical
clinical features without histological confirmation) or possible (atypical clinical features, no
apparent alternative diagnosis and no histological confirmation). Diagnosis of probable AD
can only be made when objective evidence of significant memory deterioration exists by
neuropsychological evaluation together with at least one other biological feature such as
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abnormal  CSF  biomarkers  and  specific  positron  emission  tomography  (PET)  patterns.
Patients  are evaluated using structured/semi-structured interviews and neuropsychologi‐
cal batteries with a variety of available tests to explore different aspects of cognition and
behaviour. It may be advisable to apply a quick neuropsychological test to patients with
apparent cognitive decline at  primary care level;  this  would facilitate a proper canaliza‐
tion and management of the patient. Initial evaluations of general cognitive status can be
performed using the popular Mini-Mental State Examination (MMSE) which is quick and
easy to apply and provides information on global cognitive efficiency and dementia severity,
although is not recommended for a definitive diagnosis.
The  issue  of  neuropsychiatric  syndromes  should  also  be  addressed  during  dementia
evaluation  as  their  presence  is  associated  with  a  rapid  deterioration  of  cognition.  It  is
important to notice that AD and cerebrovascular disease frequently coexist and the latter
strongly determines presence and severity of clinical symptoms; thus, taking into account
vascular risk factors and focal neurological signs as well as Hachinski Ischemic Scale results,
combined  with  neuroimaging,  serve  as  powerful  tools  to  uncover  a  mixed  dementia,
especially in elderly individuals.
The most prominent feature of AD is a decline in cognitive function initially characterized by
deficient memory for recent events, unusually repetitive omissions and difficulty to learn new
information. The Free and Cued Selective Reminding Test (FCSRT) is a useful tool to explore
these initial deficiencies in suspected AD patients. Temporo-spatial disorientation appears in
early stages of the disease and progresses towards intermediate stages, where the patient can
be disoriented in familiar places and aphasia appears with a decrease in verbal comprehension
and nominal difficulty. To evaluate the fluency and coherence of language simple and complex
orders and naming tests are used.
Confident neuropsychological markers of AD in early stages are deficiencies in episodic
memory. Neuropsychological evaluation of AD patients also finds a loss of autonomy with
disease progression from higher level to basic daily activities, for which daily living activities
tests are applied. Instrumental functions such as language, praxis and visuospatial skills start
being affected in intermediate stages of AD. Visuospatial dysfunction is a common feature in
this stage of disease and can be evaluated by drawing and copying tests. In moderate to severe
stages, difficulty to use objects and dressing apraxia can be observed as well as visual agnosia
and a visual processing dysfunction recognized by facial and object recognition tests. Working
memory and attention are usually affected by the time of diagnosis.
Deficiency in activities of daily living due to cognitive decline is essential diagnostic criteria
for dementia and has great impact on quality of life. Neuropsychological tests to evaluate this
feature allow differentiation of dementia from mild cognitive impairment (MCI). These tests
measure basic (e.g. dressing, hygiene, feeding) and instrumental (e.g. cooking, cleaning,
money management) activities. Activities of the Daily Living (ADL) and Instrumental
Activities of the Daily Living (IADL) are widely used scales and provide the advantage of
being easily applicable in primary care.
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Non-cognitive, psychiatric and behavioural alterations common to dementia such as apathy,
aggression, depression, psychosis and sleep disorders vary according to disease severity and
may fluctuate; they can also present as initial manifestations of dementia. It is believed that
neuropsychiatric alterations may even serve as clinical indicators of MCI conversion to AD.
Scales for mood and behaviour not only evaluate the presence/absence of symptoms but their
frequency, severity and impact; they can be applied to family and caregivers. The Neuro‐
psychiatric Inventory can evaluate up to 10 behavioural alterations and is considered a
standard tool, although a number of different batteries are available for this purpose. In Table
2 we provide a list of neuropsychological tests and batteries available to evaluate different
aspects of cognitive and non-cognitive alterations.
General cognitive function Cognitive Assessment System (CAS)
Dementia Rating Scale—2 (DRS-2)
Kaplan Baycrest Neurocognitive Assessment (KBNA)
Kaufman Brief Intelligence Test (K-BIT)
Mini-Mental State Examination (MMSE)
National Adult Reading Test (NART)
Neuropsychological Assessment Battery (NAB)
Raven’s Progressive Matrices (RPM)
Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)
Stanford-Binet Intelligence Scales—5th edition (SB5)
The Test of Nonverbal Intelligence—3 (TONI-3)
The Speed and Capacity of Language Processing Test (SCOLP)
Wechsler Abbreviated Scale of Intelligence (WASI)
Wechsler Adult Intelligence Scale—III (WAIS-III)
Woodcock-Johnson III Tests of Cognitive Abilities (WJ III COG)
Executive function Behavioural Assessment of the Dysexecutive Syndrome (BADS)
CANTAB
Category Test (CT)
Cognitive Estimation Test (CET)
Delis-Kaplan Executive Function System (D-KEFS)
Design Fluency Test
Five Point Test
Hayling and Brixton Tests
Ruff Figural Fluency Test (RFFT)
Self-Ordered Pointing Test (SOPT)
Stroop Test
Verbal Fluency
Wisconsin Card Sorting Test (WCST)
Attention Brief Test of Attention (BTA)
Colour Trails Test (CTT)
Comprehensive Trail Making Test (CTMT)
Conners’ Continuous Performance Test II (CPT-II)
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Integrated Visual and Auditory Continuous Performance Test (IVA + Plus)
Paced Auditory Serial Addition Test (PASAT)
Ruff 2 & 7 Selective Attention Test (2 & 7 Test)
Symbol Digit Modalities Test (SDMT),
Test of Everyday Attention (TEA)
Test of Variables of Attention (T.O.V.A.)
Trail Making Test (TMT)
Memory Autobiographical Memory Interview (AMI)
Benton Visual Retention Test (BVRT-5)
Brief Visuospatial Memory Test—Revised (BVMT-R)
Brown-Peterson Task
Buschke Selective Reminding Test (SRT)
California Verbal Learning Test-II (CVLT-II)
Doors and People Test (DPT)
Hopkins Verbal Learning Test—Revised (HVLT-R)
Recognition Memory Test (RMT)
Rey-Osterrieth Auditory Verbal Learning Test (RAVLT)
Rey Complex Figure Test (ROCF)
Rivermead Behavioural Memory Test—2th edition (RBMT-II)
Ruff-Light Trail Learning Test (RULIT)
Sentence Repetition Test
Wechsler Memory Scale—3th edition (WMS-III)
Wide Range Assessment of Memory and Learning—2th edition (WRAML2)
Language Boston Diagnostic Aphasia Examination—3th edition (BDAE-3)
Boston Naming Test—2 (BNT-2)
Dichotic listening – Words
Expressive One-Word Picture Vocabulary Test—3th edition (EOWPVT3)
Expressive Vocabulary Test (EVT)
Multilingual Aphasia Examination (MAE)
Peabody Picture Vocabulary Test—3th edition (PPVT-III)
Token Test (TT)
Visual perception Balloons Test
Bells Cancellation Test
Clock Drawing Test (CDT)
Facial Recognition Test (FRT)
Hooper Visual Organization Test (VOT)
Judgement of Line Orientation (JLO)
Visual Object and Space Perception Battery (VOSP)
Somatosensory and
olfactory function, body
orientation
Finger localization
Right-Left Orientation (RLO)
Rivermead Assessment of Somatosensory Performance (RASP)
Smell Identification Test (SIT)
Tactual Performance Test (TPT)
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Motor function Finger Tapping Test (FTT)
Grip Strength
Grooved Pegboard
Purdue Pegboard Test
Mood, personality and
adaptive functions
Beck Depression Inventory—2th edition (BDI-II)
Behaviour Rating Inventory of Executive Function (BRIEF)
Geriatric Depression Scale (GDS)
Instrumental Activities of Daily Living (IADL)
Minnesota Multiphasic Personality Inventory-2 (MMPI-2)
Personality Assessment Inventory (PAI)
Scales of Independent Behaviour—Revised (SIB-R)
Trauma Symptom Inventory (TSI)
Activities of the daily
living
Activities of the Daily Living (ADL)
Instrumental Activities of the Daily Living (IADL)
Disability Assessment for Dementia Scale
Alzheimer Disease Cooperative Study ADL Scale
Functional Activities Questionnaire
Progressive Deterioration Scale
Source: Strauss E, Sherman EMS, Spreen O. A compendium of neuropsychological tests: administration, norms, and
commentary, 3rd ed. New York: Oxford University Press; 2006.
Table 2. Tests and batteries for neuropsychological evaluation.
3.4. Neuroimaging
Imaging of the brain can reflect anatomical and physiological changes related to specific
pathological processes. Structural neuroimaging technologies such as computed tomography
(CT) and magnetic resonance imaging (MRI) provide relevant information on brain structures
and help to exclude treatable conditions while functional neuroimaging including single
photon emission computed tomography (SPECT), PET and functional magnetic resonance
imaging (fMRI) informs about brain activity status. CT and MRI on AD evaluation are used to
exclude neurosurgical lesions (tumors, subdural hematomas), search for evidence of cerebro‐
vascular lesions (stroke, white matter lesions) and identify medial temporal lobe atrophy. The
overlap of whole-brain atrophy in AD with normal aging and other dementias is considerable
and therefore lacks diagnostic value in clinical practice. Absolute values of glucose metabolism
in the hippocampus are normal in early stages of AD but decrease progressively during disease
course as detected by PET. Hypometabolism in the associative parietal cortex, external
temporal area, precuneus, posterior cingulate cortex and dorsolateral frontal cortex can be
found in patients with clear dementia symptoms.
AD is characterized by changes in neurotransmission correlating with cognitive decline,
particularly acetylcholine. A few PET tracers to measure acetylcholinesterase (AChE) and
ligands to muscarinic and nicotinic receptors have been developed on the basis of the role of
the cholinergic system in cognition and AD. AChE activity can be measured by its radioactively
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tagged analogues N-[11C]-methyl-piperidine-4-yl-propionate (11C-PMP) and N-[11C]-methyl-
piperidine-4-yl-acetate (11C-MP4A); nicotinic receptors can be measured by 11C-nicotine. A
decrease in 11C-nicotine correlates with cognition measured by MMSE [12]. Visualization of
amyloid plaques started some 15 years ago initially using Aβ monoclonal antibodies and
peptidic fragments and later small radioactively tagged Congo red, chrysamine G and
thioflavin analogues for PET and SPECT. 18F tagging may present some advantages for clinical
applications compared to 11C. Studies have shown there is less correlation between cognitive
decline and the amount of amyloid plaques in the AD brain than between cognitive decline
and the amount of neurofibrillary tangles and/or neurotransmitter activity as amyloid deposits
are observed in up to 30% of cognitively healthy aged individuals [13]. An increase in micro‐
glial activation has also been reported in AD patients using neuroimaging technologies [14].
3.5. Differential diagnosis
Even when AD is the most common dementing syndrome in the elderly, one shall not forget
that AD can share symptoms with other disorders. Medical, neurological and psychiatric
conditions to which memory loss, depression, disorientation and other symptoms can be
attributed must be also investigated for a differential diagnosis of dementia. When performing
a diagnosis, it is important to be aware of features found during the patient evaluation
providing doubt for the AD diagnosis and bear in mind that the more accurate the diagnosis
is, the better the disease can be managed. AD diagnosis can be questioned when the conditions
presented in Table 3 exist.
Feature Possible cause
Early alterations of behaviour: inappropriate social behaviour/feeding
alterations
Fronto-temporal dementia (FTD)
Early extrapyramidal signs Dementia with Lewy Bodies
(DLB)Early visual hallucinations
Early visuospatial and attention deterioration
Behavioural disturbances during REM sleep
Fluctuation of symptoms
Vascular lesions in neuroimaging
Sudden onset of symptoms
Focal neurological signs
Vascular dementia (VaD)
Early language alterations:
-Hesitant, forced speech, agrammatism
-Progressive loss of knowledge about words and objects-Progressive
decline of speech with anomia
Non-fluent progressive aphasia
Semantic dementia
Logopenic progressive aphasia
Onset with high order visuospatial dysfunction/Balint syndrome: ocular
apraxia, optic ataxia, simultagnosia
Progressive posterior cortical atrophy
Table 3. Evaluation findings suggesting a diagnosis different from AD.
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4. The search for AD biomarkers
Biomarkers for LOAD could help predict and diagnose the disease as well as follow its
progression, evaluate treatments and find new therapeutic targets. Neuroimaging technolo‐
gies, genomics, transcriptomics and proteomics approaches are being extensively used
globally to search for novel biomarkers for AD capable of detecting changes in the brain and
peripheral tissues occurring early in the disease. Nevertheless, the finding of biomarkers with
good sensitivity and specificity for AD, and furthermore, their validation, is challenging,
reason why different combinations of biomarkers, cognitive markers and risk factors may
represent a more suitable tool to pursue diagnostic sensitivity and specificity for LOAD.
4.1. Brain biomarkers
Markers of AD pathology have been extensively investigated in the brain of these patients;
unfortunately, the task has been challenging due to overlap of a number of these findings with
other brain disorders and even with normal ageing, as is the case of whole-brain atrophy.
Although some findings might still represent specific biomarkers for AD as shown by a recent
study where a decrease in grey matter diffusion values observed mainly in the posterior
cingulate gyrus and precuneus area has been suggested as a potential new biomarker for AD
in early stages [15].
However, abnormalities in brain imaging (structural and functional), cognitive markers
(neuropsychological scores) and molecules (mRNA, proteins) measured in specific brain
regions affected by AD are currently demonstrating a better potential to identify AD and
differentiate it from other disorders in a number of different combinations. Recent studies on
the Alzheimer’s Disease Neuroimaging Initiative (ADNI) subjects have shown correlations
between temporal lobe atrophy measured by serial MRI scans with CSF p-tau and tau/Aβ42
ratio as well as with cognitive markers which apparently may also be able to predict MCI-AD
conversion. Hippocampal volume loss showed to correlate with ApoE4 genotype. PET
imaging using 18F-fludeoxyglucose (FDG) showed correlations with Aβ42, but using 11C-
labelled Pittsburgh compound B (11C-PIB) to specifically bind fibrillar Aβ plaques showed
correlations not only with Aβ42 but t-tau and p-tau181 [16]. However, recently, a comparative
study suggested ADNI subjects appear to have a more aggressive pathology than population-
based samples, as observed by the rates of decline in hippocampal volume measured by MRI,
which may raise concerns about ADNI subjects not being representative of the general
population [17]. In any case, we must remember all findings should be validated in different
cohorts and here may be the point where reproducibility cannot be achieved, reason why this
has become a very active field in AD research.
4.2. Peripheral biomarkers
The search for easily available biomarkers for AD has lead scientists in the past years to
investigate a number of molecules in CSF and blood components. From a variety of these
studies several molecules were proposed as potential blood biomarkers for the disease (Table
4), although some results remained controversial. Until now, the best biomarker validated for
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AD diagnosis is the CSF tau/Aβ42 ratio. Other biomarkers in CSF have been investigated though
and, recently, protein markers of DNA damage have shown potential as biomarkers for AD
and other dementias [18].
Markers involved in APP and Aβ metabolisms
Aβ peptides (total Aβ, Aβ40 and Aβ42)
Brain-plasma Aβ flux
Aβ autoantibodies
APP platelet isoforms
BACE1 activity
Markers related to cholesterol metabolism and vascular disease
Cholesterol
24S-hydroxycholesterol
ApoE
Lp(a)
Homocysteine
Markers of oxidation
Antioxidant levels (carotene, lycopene, vitamins A, C and E, urate, bilirubin)
Lipid peroxidation (F2-isoprostanes, 4-hydroxynonenal)
Markers of inflammation
C reactive protein
IL-1β
TNF-α
IL-6 and its receptor
α1-antichymotrypsin
Other proposed markers
Total tau (t-tau) and phosphorilated tau (p-tau)
p97
GSK3
MAO-B
Phospholipase-A2
α2-macroglobulin
Complement factor H (CFH)
Desmosterol
Table 4. Proposed blood biomarkers for AD.
In recent years, the approach for biomarker discovery has changed, now focusing on pattern
recognition and combinations of different markers to identify panels capable of differentiating
AD from healthy control subjects and, in some cases, from other brain disorders. As the work
on this field has been so extensive we will limit ourselves now to briefly mention some of the
recent biomarker findings reported principally in blood plasma (Table 5), where protein
profiles have been extensively analysed in AD, MCI and control subjects using a wide range
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of technologies. We shall not forget serum and blood cells are also a potential source of
pathologic alterations reflecting disease.
Sample Cohort Panel Change Ref.
Plasma AD and controls
from the Australian
Imaging Biomarker
and Lifestyle study
(AIBL)
cortisol, pancreatic polypeptide, insulin like
growth factor binding protein 2, β2
microglobulin, vascular cell adhesion molecule
1, carcinoembryonic antigen, matrix
metalloprotein 2, CD40, macrophage
inflammatory protein 1α, superoxide
dismutase, and homocysteine
Increase [19]
apolipoprotein E, epidermal growth factor
receptor, hemoglobin, calcium, zinc,
interleukin 17, and albumin
Decrease
Plasma MCI, AD and
controls from ADNI
eotaxin 3, pancreatic polypeptide, N-terminal
protein B-type brain natriuretic peptide,
tenascin C
Increase [20]
IgM and ApoE Decrease
Peripheral blood
mononuclear
cells (PBMCs)
LOAD and controls fatty acid amide hydrolase (FAAH) gene
expression, protein levels and activity
Increase [21]
Plasma MCI-AD converters
and controls from
ADNI
α2-macroglobulin, angiotensinogen,
apolipoprotein A-II (ApoA-II), ApoE,
betacellulin (BTC), Fas ligand (FasL), heparin-
binding EGF-like growth factor (HB-EGF),
macrophage inflammatory protein-1α
(MIP-1α), peptide YY (PYY), m glutamic
oxaloacetic transaminase (SGOT), transthyretin
(TTR)
Signature [22]
Plasma AD and controls ANG-2, CCL5, CCL7, CCL15, CCL18, CXCL8,
EGF, G-CSF, GDNF, ICAM-1, IGFBP-6, IL-1α, IL-3,
IL-11, M-CSF, PDGF-BB, TNF-α, TRAIL-R4
Signature [23]
Plasma AD and controls EGF, PDG-BB and MIP-1δ Not stated [24]
AD and other
dementias
TRAIL-R4
Serum AD and controls miR-137, -181c, -9, -29a/b Down-
regulated
[25]
Plasma MCI, AD and
control from
AddNeuroMed
complement components C3 and C3a,
complement factor-I, γ-fibrinogen and
alpha-1-microglobulin
Associate with
whole-brain
volume
[26]
Table 5. Recent findings on blood biomarkers for AD.
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4.2.1. Expression of MAPT, APP, NCSTN and BACE1 in lymphocytes
Neurofibrillary tangles and amyloid plaques are hallmarks in the AD brain involving the
microtubule-associated protein tau (MAPT) and Aβ peptides generated from the amyloid
precursor protein (APP) by sequential cleavage of the β- and γ-secretases, nicastrin (NCSTN)
being a major component of the latter. These molecules have been widely investigated in the
brain; nevertheless, little is known about their expression in peripheral cells. The established
role of inflammation in the AD pathology lead us to question how these major genes express
in peripheral lymphocytes and, furthermore, whether their expression may correlate with
common medical conditions in the elderly that have been identified as risk factors for LOAD.
a. Samples
To address this question, we collected blood samples from a total of 72 subjects, including 48
healthy individuals divided into 4 groups by age (25 to 92 years of age), 12 clinically diagnosed
AD patients and 12 patients suffering from other brain disorders (vascular dementia-VaD-,
Parkinson’s disease-PD-, traumatic brain injury-TBI-, cerebrovascular events-CVE-, psychotic
disorder) as a comparative group named NP (Table 6). All patients had been previously
diagnosed by appropriate professionals in the private practice and healthy subjects volun‐
teered, making this a small population-based cohort with exploratory purposes. For all
subjects, blood pressure was measured and history was briefly collected; for all patients,
interviews with family members were also performed. All patients are participants in our
neuro-rehabilitation program [27] and samples were collected at the time of enrolment.
Group n Mean age Diagnosis
I 12 30
Cognitively healthy
II 12 44
III 12 58
IV 12 80
AD 12 80 LOAD
NP 12 78 PD, MCI, VaD, CVE, TBI, psychotic disorder/ schizophrenia
Table 6. Basic characteristics of the study groups.
b. Methodology
After collection, serum was separated from whole blood to quantify total cholesterol, glucose
and triglycerides. Lymphocytes were isolated from EDTA whole blood using Lymphoprep
(Nycomed Pharma). After washing the pellet, total RNA was extracted from lymphocytes by
the TRIzol method (Invitrogen). Endpoint RT-PCR was selected to semiquantify MAPT, APP,
NCSTN and the β-secretase BACE1 expression levels because of our strong interest in the use
of the most easily available technologies for small research and clinical laboratories. Glycer‐
aldehyde-3-phosphate-dehydrogenase (GAPDH) was the housekeeping gene of choice.
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c. Data analysis
Gene expression values were compared between study groups using Student’s t and Mann-
Whitney’s U tests. Associations between gene expression levels and between expression with
raw values of the analysed risk factor conditions were investigated using Spearman’s corre‐
lation coefficients. Differences were considered significant at p<0.05.
d. Main findings
As the full report of this exploratory study is currently under review for publication, we
will limit ourselves here to share only the most relevant of our results. From the four genes
analysed,  we  were  not  able  to  detect  NCSTN  in  any  AD  subjects,  therefore  showing
significant differences between the AD group and all the others, but particularly differing
from the group of other brain disorders which showed the highest expression levels for this
study  (Figure  1).  We  also  investigated  the  prevalence  of  commonly  elevated  variables
increasing the risk for AD: blood pressure (taken as systolic/diastolic pressure and pulse),
glucose,  total  cholesterol  and  triglycerides.  High  serum  triglycerides  and  cholesterol
prevailed  in  the  whole  study  population  whereas  the  AD  group  showed  no  greater
prevalence of any of these conditions. Correlation analyses associated NCSTN expression
in  lymphocytes  with  that  observed  for  APP  and  BACE1,  as  well  as  with  serum  total
cholesterol levels in the whole study population but, when separated by groups, NCSTN
expression only correlated with cholesterol levels in the group NP.
Figure 1. NCSTN relative expression in lymphocytes.
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5. Conclusions
Late-onset  Alzheimer’s  disease  (LOAD)  is  the  most  common  dementia  in  the  aged
population and therefore great efforts to discover the factors conferring an increased risk
for  this  disease  and  biomarkers  able  to  help  in  its  diagnosis  and  prognosis  are  made
worldwide.  These  intensively  active  fields  of  research  have  produced huge  amounts  of
information, some of which have been controversial but also a good volume showing real
potential and waiting to seek further replication and validation. However, while research
on biomarkers for AD struggles with the challenge of sensibility, specificity and reprodu‐
cibility in different cohorts, it is of major importance to assure the best possible perform‐
ance when clinically diagnosing a patient with LOAD. Clinical diagnosis of dementias may
be  a  bit  of  a  long  process  which  requires  some  expertise  and  must  include  specific
laboratory  and  neuropsychological  tests  as  well  as  imaging  of  the  brain  and  family
interviews.  An  accurate  diagnosis  has  implications  on  therapeutic  approaches,  disease
progression and costs, quality of life of patients, family and caregivers and other impor‐
tant aspects for disease management.
We previously reported the establishment of a neuro-rehabilitation program for AD and
other  neuropsychological  disorders  in  our  locality  [27]  and  made  brief  mention  of  a
biomarker study for which now we reported results on this occasion. Our major interest
resides in using the most easily and widely available technologies for biomarker discov‐
ery and therapeutic approaches which could be directed to the general population around
the globe in a cost effective manner. Even when our work is in the very first stages of this
research, we seek to continue our studies in larger cohorts, including more variables and
using better technologies.
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